v3.26.1
Consolidated Statements of Changes in Shareholders’ Equity
¥ in Thousands, $ in Thousands
Ordinary shares
Class A
CNY (¥)
shares
Ordinary shares
Class A
USD ($)
shares
Ordinary shares
Class B
CNY (¥)
shares
Ordinary shares
Class B
USD ($)
shares
Additional paid-in capital
CNY (¥)
Additional paid-in capital
USD ($)
Statutory reserve
CNY (¥)
Statutory reserve
USD ($)
Retained earnings (deficit)
CNY (¥)
Retained earnings (deficit)
USD ($)
Accumulated Other Comprehensive income (deficit)
CNY (¥)
Accumulated Other Comprehensive income (deficit)
USD ($)
Total Zhengye Biotechnology Holding Limited’s shareholders’ equity
CNY (¥)
Total Zhengye Biotechnology Holding Limited’s shareholders’ equity
USD ($)
Non- controlling interests
CNY (¥)
Non- controlling interests
USD ($)
CNY (¥)
USD ($)
Balance (in Dollars) ¥ 1 [1]   ¥ 7 [1]   ¥ 203,150   ¥ 27,565   ¥ 65,774     ¥ 296,497   ¥ 60,370   ¥ 356,867  
Balance (in Shares) | shares [1] 5,666,376 5,666,376 40,000,000 40,000,000                            
Balance at Dec. 31, 2022 ¥ 1 [1]   ¥ 7 [1]   203,150   27,565   65,774     296,497   60,370   356,867  
Balance (in Shares) at Dec. 31, 2022 | shares [1] 5,666,376 5,666,376 40,000,000 40,000,000                            
Net income (loss) [1]   [1]       31,457     31,457   6,052   37,509  
Foreign Currency Translation Adjustment                                  
Transfer to statutory reserve [1]   [1]     3,746   (3,746)          
Dividend [1]   [1]       (55,104)     (55,104)     (55,104)  
Balance at Dec. 31, 2023 ¥ 1 [1]   ¥ 7 [1]   203,150   31,311   38,381     272,850   66,422   339,272  
Balance (in Shares) at Dec. 31, 2023 | shares [1] 5,666,376 5,666,376 40,000,000 40,000,000                            
Balance (in Dollars) ¥ 1 [1]   ¥ 7 [1]   203,150   31,311   38,381     272,850   66,422   339,272  
Balance (in Shares) | shares [1] 5,666,376 5,666,376 40,000,000 40,000,000                            
Net income (loss) [1]   [1]       11,311     11,311   2,159   13,470  
Foreign Currency Translation Adjustment [1]   [1]         3   3     3  
Transfer to statutory reserve [1]   [1]     1,336   (1,336)          
Dividend [1]   [1]       (205)     (205)     (205)  
Balance at Dec. 31, 2024 ¥ 1 [1]   ¥ 7 [1]   203,150   32,647   48,151   3   283,959   68,581   352,540  
Balance (in Shares) at Dec. 31, 2024 | shares [1] 5,666,376 5,666,376 40,000,000 40,000,000                            
Balance (in Dollars) ¥ 1 [1]   ¥ 7 [1]   203,150   32,647   48,151   3   283,959   68,581   352,540  
Balance (in Shares) | shares [1] 5,666,376 5,666,376 40,000,000 40,000,000                            
Net income (loss) [1]   [1]       (69,784)     (69,784)   (13,184)   (82,968) $ (11,867)
Foreign Currency Translation Adjustment     [1]         (1,929)   (1,929)     (1,929) (275)
Issuance of shares in initial public offering [1]   [1]   37,602         37,602     37,602  
Issuance of shares in initial public offering (in Shares) | shares [1] 1,725,000 1,725,000                                
Shareholders interest contribution [1]   [1]             1,470   1,470  
Balance at Dec. 31, 2025 ¥ 1 [1] [1] ¥ 7 [1] $ 1 [1] 240,752 $ 34,427 32,647 $ 4,668 (21,633) $ (3,099) (1,926) $ (275) 249,848 $ 35,722 56,867 $ 8,132 306,715 43,854
Balance (in Shares) at Dec. 31, 2025 | shares [1] 7,391,376 7,391,376 40,000,000 40,000,000                            
Balance (in Dollars) ¥ 1 [1] [1] ¥ 7 [1] $ 1 [1] ¥ 240,752 $ 34,427 ¥ 32,647 $ 4,668 ¥ (21,633) $ (3,099) ¥ (1,926) $ (275) ¥ 249,848 $ 35,722 ¥ 56,867 $ 8,132 ¥ 306,715 $ 43,854
Balance (in Shares) | shares [1] 7,391,376 7,391,376 40,000,000 40,000,000                            
[1] As of December 31, 2025, share reclassification was retroactively restated with effective date of March 24, 2026.